Literature DB >> 18284928

The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study.

Anna O G Goodman1, Peter R Murgatroyd, Gema Medina-Gomez, Nigel I Wood, Nicholas Finer, Antonio J Vidal-Puig, A Jennifer Morton, Roger A Barker.   

Abstract

Huntington's disease (HD) is a debilitating autosomal dominant, neurodegenerative disease with a fatal prognosis. Classical symptoms include motor disturbances, subcortical dementia and psychiatric symptoms but are not restricted to this triad. Patients often experience other problems such as weight loss, although why and when this occurs in the disease course is not known. We studied metabolism using whole body indirect calorimetry in both early stage HD patients and in the R6/2 transgenic mouse model of HD, at times before and after they displayed signs of disease. Using this combined approach we found that patients with early HD tended to be in negative energy balance for reasons not related to their movement disorder, which was paralleled in the transgenic R6/2 mice. These mice had significantly elevated total energy expenditure as they developed overt disease with weight loss due primarily to a loss of muscle bulk. This study has shown for the first time that in HD there is the development of early negative energy balance, which in turn may cause weight loss with loss of muscle bulk in particular. The reason for this is not known but may reflect a catabolic state secondary to hypothalamic pathology, as abnormalities have been reported in the hypothalamus early in the disease course.

Entities:  

Mesh:

Year:  2008        PMID: 18284928     DOI: 10.1016/j.expneurol.2007.12.026

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  43 in total

1.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 2.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

4.  Microcirculation response to local cooling in patients with Huntington's disease.

Authors:  Ziva Melik; Jan Kobal; Ksenija Cankar; Martin Strucl
Journal:  J Neurol       Date:  2011-10-20       Impact factor: 4.849

5.  Neurodegenerative disease: Tracking disease progress in Huntington disease.

Authors:  Roger A Barker; Sarah L Mason
Journal:  Nat Rev Neurol       Date:  2011-03-15       Impact factor: 42.937

Review 6.  Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Authors:  Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

7.  Measures of growth in children at risk for Huntington disease.

Authors:  Jessica K Lee; Kathy Mathews; Bradley Schlaggar; Joel Perlmutter; Jane S Paulsen; Eric Epping; Leon Burmeister; Peg Nopoulos
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

8.  Increased catabolic state in spinocerebellar ataxia type 1 patients.

Authors:  Anja Mähler; Jochen Steiniger; Matthias Endres; Friedemann Paul; Michael Boschmann; Sarah Doss
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.